Unknown

Dataset Information

0

A multivalent Plasmodium falciparum circumsporozoite protein-based nanoparticle malaria vaccine elicits a robust and durable antibody response against the junctional epitope and the major repeats.


ABSTRACT: Plasmodium falciparum (Pf) malaria continues to cause considerable morbidity and mortality worldwide. The circumsporozoite protein (CSP) is a particularly attractive candidate for designing vaccines that target sporozoites-the first vertebrate stage in a malaria infection. Current PfCSP-based vaccines, however, do not include epitopes that have recently been shown to be the target of potent neutralizing antibodies. We report the design of a SpyCatcher-mi3-nanoparticle-based vaccine presenting multiple copies of a chimeric PfCSP (cPfCSP) antigen that incorporates these important "T1/junctional" epitopes as well as a reduced number of (NANP)n repeats. cPfCSP-SpyCatcher-mi3 was immunogenic in mice eliciting high and durable IgG antibody levels as well as a balanced antibody response against the T1/junctional region and the (NANP)n repeats. Notably, the antibody concentration elicited by immunization was significantly greater than the reported protective threshold defined in a murine challenge model. Refocusing the immune response toward functionally relevant subdominant epitopes to induce a more balanced and durable immune response may enable the design of a more effective second generation PfCSP-based vaccine.

SUBMITTER: Pendyala G 

PROVIDER: S-EPMC10354751 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

A multivalent <i>Plasmodium falciparum</i> circumsporozoite protein-based nanoparticle malaria vaccine elicits a robust and durable antibody response against the junctional epitope and the major repeats.

Pendyala Geetanjali G   Calvo-Calle J Mauricio JM   Moreno Alberto A   Kane Ravi S RS  

Bioengineering & translational medicine 20230328 4


<i>Plasmodium falciparum</i> (<i>Pf</i>) malaria continues to cause considerable morbidity and mortality worldwide. The circumsporozoite protein (CSP) is a particularly attractive candidate for designing vaccines that target sporozoites-the first vertebrate stage in a malaria infection. Current <i>Pf</i>CSP-based vaccines, however, do not include epitopes that have recently been shown to be the target of potent neutralizing antibodies. We report the design of a SpyCatcher-mi3-nanoparticle-based  ...[more]

Similar Datasets

| S-EPMC8795123 | biostudies-literature
| S-EPMC8016880 | biostudies-literature
| S-EPMC7082059 | biostudies-literature
| S-EPMC7820318 | biostudies-literature
| S-EPMC9992340 | biostudies-literature
| S-EPMC9810210 | biostudies-literature
| S-EPMC10110616 | biostudies-literature
| S-EPMC8426336 | biostudies-literature
| S-EPMC5715787 | biostudies-literature
| S-EPMC11561850 | biostudies-literature